“The way I approach patient education conversations is to discuss it, address it, but not to emphasize it. I really like to focus on what the drug is. I mention if it’s a biosimilar, I explain it, I give resources if they want it, but I really try to focus on the things that they’re going to need to know in order to help be part of their care, but have readily available information to give them if they want more,” ONS affiliate member Rowena (Moe) Schwartz, PharmD, BCOP, professor of pharmacy practice at the University of Cincinnati in Ohio, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS during a discussion about the basics of biosimilars for nurses and patients. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.
Music Credit: “Fireflies and Stardust” by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by February 3, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center’s Commission on Accreditation.
Learning outcome: The learner will report a gain in knowledge related to biosimilars.
To discuss the information in this episode with other oncology nurses, visit the ONS Communities.
To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
Highlights From Today’s Episode
“For generic products, it’s important that they are the same as the brand-name product. The differences there tend to be only inactive ingredients. And for a biosimilar, it’s very similar to that biologic, and it’s supposed to have no clinically meaningful differences from the reference product.” Timestamp (TS) 06:46
“There was a lot of discussion about how would we identify when a patient got a biosimilar? A naming convention was implemented in 2017 that would help address understanding what particular drug a patient got at every point in care. The naming is done so that you have the core nonproprietary name, and then there’s a four letter suffix added. . . . That naming convention was for all biologics that were approved that U.S. Food and Drug Administration naming guidance was implemented. And it’s so that when that biologic comes out, if a biosimilar is ever approved, you would be able to differentiate.” TS 12:50
“The way I approach patient education conversations is to discuss it and address it but not to emphasize it. Because then I think it almost creates a question in the person’s mind, ‘Is this as good?’ We saw that with generics, we see that with biosimilars, and I really think that people need to know that this is the drug that you’re using. They’re pretty much overwhelmed, just even about the side effects. So I really like to focus on this is what the drug is, I mention if it’s a biosimilar, I explain it, I give resources if they want it, but I really try to focus on the things that they’re going to need to know in order to help be part of their care but have readily available information to give them if they want more.” TS 17:19
“As we get more of these products, as we use them, I think that the healthcare team is becoming more comfortable. And I think that is definitely felt by patients, caregivers, and families. As people get more comfortable with the data and the understanding of these, I think that will help patients and kind of flow over to the whole team.” TS 19:06